Date: 2012-10-08
Type of information: R&D agreement
Compound: Mimopath® platform
Company: Mucosis (The Netherlands) Crucell, a J&J company (The Netherlands - USA)
Therapeutic area: Infectious diseases
Type agreement: R&D
licensing
Action mechanism: The Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.
Disease:
Details: Mucosis BV, a clinical-stage Dutch biotechnology company developing innovative mucosal vaccines, has signed a Research and License Option Agreement with Crucell Holland, the Dutch developer of vaccines and antibodies. In the research collaboration, Crucell will make use of Mucosis\'s proprietary Mimopath® platform technology and know-how in Crucell\'s program for developing undisclosed novel vaccines to combat infectious diseases. Under the terms of the agreement, Mucosis will receive upfront payments and could receive additional payments on the achievement of agreed upon milestones.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
